Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196818 | 0.86 | LMNA (0.56) | LMNAMAPTCYP1A2CYP2D6KMT2A | |
| SCHEMBL3281654 | 0.82 | LMNA (0.46) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL9900539 | 0.81 | KMT2A (0.55) | LMNAMAPTKMT2AHTTSMN1; SMN2 | |
| SCHEMBL9900428 | 0.80 | LMNA (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL3281618 | 0.80 | LMNA (0.45) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL5220298 | 0.80 | LMNA (0.46) | LMNAKMT2AHTTSMN1; SMN2MEN1 | |
| SCHEMBL3280739 | 0.79 | LMNA (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL29998765 | 0.79 | LMNA (0.51) | LMNAMAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL29106050 | 0.79 | LMNA (0.46) | LMNAMAPTKMT2AHTTSMN1; SMN2 | |
| SCHEMBL8515361 | 0.78 | SMO (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | LMNA 4184/4885MAPT 3183/4885CYP1A2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.